open access

Vol 82, No 8 (2011)
ARTICLES
Get Citation

18F-FDG PET-CT and USG/CT in benign and malignant ovarian tumors with postoperative histopathological correlation

Umur Kuyumcuoğlu, Ali Ifran Guzel, Yusuf Celik, Mahmut Erdemoğlu, Halil Komek
Ginekol Pol 2011;82(8).

open access

Vol 82, No 8 (2011)
ARTICLES

Abstract

Abstract Objectives: The role of 18F-FDG (18F fluorodeoxyglucose) PET/CT** (Positron emission tomography) in the diagnosis, treatment and follow up of benign and malignant ovarian tumors had been investigated previously. The objective of the following study was to evaluate the predictive value of PET/CT in benign and malignant ovarian tumors and compare with computerized tomography and post-operative pathology. Materials and methods: In this retrospective study, a total of sixty nine cases with benign or malignant pelvic masses underwent laparotomy at our clinic. Postoperative pathology of the patients was recorded and PET/CT results were compared with ultrasonography, computerized tomography and postoperative pathology. Results: The ROCs and AUCs values four predictors were shown in Figure 1. The AUCs (95 % CI) values calculated for CA 125, ultrasonography (USG), PET/CT and CT were as follows: 0.855(0.752-0.958), 0.703(0.540-0.866), 0.681(0.514-0.848) and 0.631(0.463-0.799) respectively. CA 125 has the highest AUC value in order to predict the malignant potential of the patient. USG has the highest AUC value between the imaging techniques, following PET/CT and CT. Conclusion: According to this study, among four modalities that distinguish malignant potential preoperatively; CA125 is the best parameter. USG and PET provide similar benefits in detecting malignant ovarian masses preoperatively. Both of these parameters are superior to CT. Combination of CA125, USG and PET/CT may be useful in detecting malignant ovarian masses preoperatively, resulting in less invasive surgeries. ** 18F-FDG (18F fluorodeoxyglucose) PET/CT will be used as the PET/CT, later in this article.

Abstract

Abstract Objectives: The role of 18F-FDG (18F fluorodeoxyglucose) PET/CT** (Positron emission tomography) in the diagnosis, treatment and follow up of benign and malignant ovarian tumors had been investigated previously. The objective of the following study was to evaluate the predictive value of PET/CT in benign and malignant ovarian tumors and compare with computerized tomography and post-operative pathology. Materials and methods: In this retrospective study, a total of sixty nine cases with benign or malignant pelvic masses underwent laparotomy at our clinic. Postoperative pathology of the patients was recorded and PET/CT results were compared with ultrasonography, computerized tomography and postoperative pathology. Results: The ROCs and AUCs values four predictors were shown in Figure 1. The AUCs (95 % CI) values calculated for CA 125, ultrasonography (USG), PET/CT and CT were as follows: 0.855(0.752-0.958), 0.703(0.540-0.866), 0.681(0.514-0.848) and 0.631(0.463-0.799) respectively. CA 125 has the highest AUC value in order to predict the malignant potential of the patient. USG has the highest AUC value between the imaging techniques, following PET/CT and CT. Conclusion: According to this study, among four modalities that distinguish malignant potential preoperatively; CA125 is the best parameter. USG and PET provide similar benefits in detecting malignant ovarian masses preoperatively. Both of these parameters are superior to CT. Combination of CA125, USG and PET/CT may be useful in detecting malignant ovarian masses preoperatively, resulting in less invasive surgeries. ** 18F-FDG (18F fluorodeoxyglucose) PET/CT will be used as the PET/CT, later in this article.
Get Citation

Keywords

PET/CT, Benign ovarian tumors, malignant ovarian tumors, Predictive Value of Tests

About this article
Title

18F-FDG PET-CT and USG/CT in benign and malignant ovarian tumors with postoperative histopathological correlation

Journal

Ginekologia Polska

Issue

Vol 82, No 8 (2011)

Bibliographic record

Ginekol Pol 2011;82(8).

Keywords

PET/CT
Benign ovarian tumors
malignant ovarian tumors
Predictive Value of Tests

Authors

Umur Kuyumcuoğlu
Ali Ifran Guzel
Yusuf Celik
Mahmut Erdemoğlu
Halil Komek

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk
tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl